NSE filing, NSE: VILINBIO. Summary written from the filing by ALFA Finder's alert engine.
Vilin Bio Med Ltd: key numbers
- Share price
- ₹50.85
- Market cap
- ₹77.55 Cr
- Revenue (annual)
- ₹42.26 Cr
- Net profit (annual)
- ₹1.93 Cr
- P/E (TTM)
- 40.2×Sector 46.1×
- Promoter holding
- 56.65%+0.00% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vilin Bio Med Ltd
All →Vilin Bio Med Other Announcement
Vilin Bio Med voluntarily filed its Integrated Corporate Governance Report for the quarter ended September 30, 2026, despite being exempt as an NSE Emerge listed entity. No material business transaction or decision is disclosed.
Vilin Bio Med Acquisition
Vilin Bio Med held NCLT-convened meetings to approve a scheme of amalgamation with Chemgenix Laboratories. Voting results remain pending in the Scrutinizer's report.
Vilin Bio Med Merger & Restructuring
Vilin Bio Med Limited announced an NCLT-convened meeting on October 15, 2026, to vote on a Scheme of Arrangement with Chemgenix Laboratories Private Limited.
Vilin Bio Med Board Meeting Date
Vilin Bio Med Limited scheduled a board meeting for September 18, 2026, to consider an amalgamation proposal. Trading window remains closed until September 20, 2026.
Vilin Bio Med Acquisition
Vilin Bio Med disclosed NCLT Hyderabad allowed its amalgamation with Chemgenix Laboratories Pvt Ltd. The order directs convening shareholder and creditor meetings for both companies.
Vilin Bio Med Annual General Meeting
Vilin Bio Med Limited conducted its 20th Annual General Meeting on September 2, 2026, to discuss financial statements, director appointments, and related party transactions.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.